Skip to main content
PR HealthPRs

Dalrada Corporation launches Empower Genomics subsidiary of Dalrada Health

By May 11, 2021August 13th, 2022No Comments

SAN DIEGO, CA – MAY 11, 2021 – Dalrada Corporation (OTCQB: DFCO ,“Dalrada”) is pleased to announce to its shareholders and the public that its subsidiary, Dalrada Health’s Empower Genomics, has launched a custom labeled suite of genomics tests – Pharmacogenomics (PGx), Cannabis DNA, Nutrition & Diet, and Exercise & Fitness – as an information service for healthcare practitioners, researchers, and individuals to identify ways to improve overall well-being. Empower Genomics specializes in product development, testing, analysis, HIPAA-compliant technology, sales, and marketing. The need for precision medicine is worldwide. The global genomics market size is projected to reach USD 54.4 billion by 2025 from USD 22.7 billion in 2020, at a CAGR of 19.0% during the forecast period.

Software and technology are the foundation for ensuring confidentiality of personal data. Empower Genomics makes this secure process easy with ordering a test kit, submitting a saliva sample, and in weeks reviewing data through a secure portal individually or with the guidance of a physician.

Genomics testing is used for creating visibility to gene alterations in the genetic code and for identifying genetic markers associated with the characteristic of a disease or a health condition. Testing a person’s genetic traits helps to better understand how their nervous system and body will react to food sensitivity and allergies, metabolic health factors, vitamin deficiencies, factors for fitness strength, recovery, performance, and more. Empower Genomics tests that reveal an individual’s genetic factors currently include:

Pharmacogenomics (PGx) – analyzes how a person’s genes respond to specific medications.

Cannabis DNA – determines 13 genetic traits that reveal which phytocannabinoids (including hemp cannabidiol “CBD” and cannabis) maximize an individual’s wellness benefits.

Nutrition & Diet – reveals 43 genetic traits related to diet, eating behaviors, nutritional needs, and more.

Exercise & Fitness – provides unfiltered access to how bodies respond to physical exercise by identifying 31 genetic traits that are essential including strength, recovery, and performance.

Empower Genomics’ product line complements Dalrada Health’s suite of products with common target markets, and a support system of technology and data analytics leveraging Prakat’s healthcare systems & engineering expertise.

About Dalrada Health

A wholly-owned subsidiary of Dalrada Financial Corp., Dalrada Health is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit

About Prakat Solutions

Prakat Solutions Inc. is a technology solutions company specializing in test engineering, accessibility engineering, product engineering, and application modernization. The company partners with clients to create transparent, value-based relationships by leveraging the extensive experience of its team and by providing innovative solutions in a wide range of technology domains that ultimately enable customers to successfully attain their business goals. The Prakat work culture is based on the belief that, “we believe in what we do; we do what we love.” Prakat is an ISO 9001-certified company with several Fortune 1000 customers. With its main engineering center in Bangalore, India, the company also has offices in Dallas, TX, Denver, CO, and San Diego, CA. The Prakat team provides end-to-end product engineering services across various domains including banking and financial services, telecom, retail, healthcare, manufacturing, legal, and IT infrastructure. For more information, please visit

About Dalrada (DFCO)

Dalrada Corporation (OTCQB: DFCO ,“Dalrada”) solves real-world problems by producing innovation-focused and technologically centered solutions on a global level. Delivering next-generation manufacturing, engineering, and healthcare products and services designed to propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital. The Company and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. For more information, visit or call 1-858-283-1253.


Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

# # #

Skip to content